Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Delayed Graft Function Clear all
Recruiting Phase 1Phase 2 Interventional

Immune Tolerance Induction After Liver Transplantation

NCT07269041
View directory record Official record
Conditions
Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions
Donor Hematopoietic Stem and Progenitor Cell Infusion
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 2 Interventional

Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

NCT01794663
View directory record Official record
Conditions
Delayed Graft Function
Interventions
OPN-305, Placebo
Drug
Lead sponsor
Opsona Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Jul 21, 2026, 11:24 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

NCT01878786
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA)
Drug
Lead sponsor
Matthew Cooper
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Jul 21, 2026, 11:24 AM EDT
Terminated Phase 4 Interventional

A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors

NCT00217152
View directory record Official record
Conditions
Kidney Transplantation, Delayed Graft Function
Interventions
CellCept
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2011 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 2 Interventional

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

NCT00235300
View directory record Official record
Conditions
Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
Interventions
Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab)
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jul 21, 2026, 11:24 AM EDT
Not listed Phase 2 Interventional

Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function

NCT01837043
View directory record Official record
Conditions
Delayed Graft Function, Kidney Transplant
Interventions
Belatacept, Calcineurin Inhibitor
Drug
Lead sponsor
Nair, Vinay, D.O.
Individual
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Jul 21, 2026, 11:24 AM EDT
Active, not recruiting Phase 2 Interventional

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096
View directory record Official record
Conditions
Delayed Graft Function
Interventions
ARGX-117, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Withdrawn Phase 2 Interventional

Delayed Renal Allograft Function and Furosemide Treatment

NCT02312115
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Furosemide, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2016 · Synced Jul 21, 2026, 11:24 AM EDT
Active, not recruiting No phase listed Observational

Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation

NCT04414111
View directory record Official record
Conditions
DGF, Kidney Transplant; Complications
Interventions
Highly suppressive Treg measurement
Diagnostic Test
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
San Bernardino, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 21, 2026, 11:24 AM EDT
Completed No phase listed Observational

Biomarkers of Aging as Predictors of Kidney Transplant Function

NCT02335333
View directory record Official record
Conditions
Delayed Graft Function, Other Complications of Kidney Transplant
Interventions
No treatment
Other
Lead sponsor
Sapere Bio
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 4 Interventional Results available

Envarsus in Delayed Graft Function (E-DGF)

NCT03864926
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Envarsus XR, Tacrolimus
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Jul 21, 2026, 11:24 AM EDT
Terminated Phase 1 Interventional

Contrast-Enhanced Ultrasound for Kidney Transplant

NCT02911714
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Lumason Contrast-Enhanced Ultrasound
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 21, 2026, 11:24 AM EDT
Not listed Phase 2 Interventional

Study to Improve Renal Function After Kidney Transplantation

NCT01286727
View directory record Official record
Conditions
Delayed Graft Function
Interventions
BB3
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
San Diego, California • Washington D.C., District of Columbia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 4 Interventional Results available

Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients

NCT02152345
View directory record Official record
Conditions
Implant or Graft; Rejection
Interventions
Belatacept, Tacrolimus, Mycophenolate, rATG, Methylprednisolone, Renal transplant
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Jul 21, 2026, 11:24 AM EDT
Not listed Phase 2 Interventional

YSPSL for Prevention of Delayed Graft Function in Cadaveric Liver Transplantation

NCT00450398
View directory record Official record
Conditions
Liver Diseases
Interventions
YSPSL, Placebo
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Jul 21, 2026, 11:24 AM EDT
Recruiting Not applicable Interventional

Deceased Donor Kidney Storage at 10 Celsius Versus Conventional Storage

NCT07385651
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Chronic Kidney Disease (Stages 4 and 5), Kidney Transplantation Recipients
Interventions
10˚C deceased donor kidney storage using Traferox XPort
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 3 Interventional

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

NCT02610296
View directory record Official record
Conditions
Delayed Graft Function
Interventions
QPI-1002, Placebo
Drug · Other
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jul 21, 2026, 11:24 AM EDT
Not yet recruiting No phase listed Observational

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

NCT07645599
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
Diagnostic Test · Drug
Lead sponsor
Roderick Tan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Terminated Early Phase 1 Interventional

Belatacept for Renal Transplant Recipients With Delayed Graft Function

NCT02134288
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Belatacept, Everolimus
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Jul 21, 2026, 11:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation

NCT04005469
View directory record Official record
Conditions
Ischemia Reperfusion Injury, Delayed Graft Function
Interventions
Treprostinil
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 21, 2026, 11:24 AM EDT
Completed Phase 3 Interventional

Remote Ischemic Preconditioning In Abdominal Organ Transplantation

NCT00975702
View directory record Official record
Conditions
Kidney Disease, Liver Disease, Pancreas Disease
Interventions
RIPC by Inflation of Pneumatic Tourniquet
Procedure
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Jul 21, 2026, 11:24 AM EDT
Terminated Phase 4 Interventional Results available

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

NCT00931255
View directory record Official record
Conditions
Kidney Transplant, Delayed Graft Function
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 21, 2026, 11:24 AM EDT